Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Yang Min Ning"'
Autor:
Jenn W, Sellers, Camelia M, Mihaescu, Kassa, Ayalew, Phillip D, Kronstein, Bei, Yu, Yang-Min, Ning, Miguel, Rodriguez, LaKisha, Williams, Ni A, Khin
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:753-764
Background The United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have collaborated in good clinical practice (GCP) inspections since September 2009. The two agencies operate under different regulatory frameworks for
Autor:
Andrea B. Apolo, Jane B. Trepel, Liang Cao, Donald P. Bottaro, Yang-Min Ning, Howard L. Parnes, Elad Sharon, John J. Wright, Howard Streicher, Antoun Toubaji, Maria Merino, William D. Figg, Vladimir Valera, Heather J. Chalfin, Sandeep Gurram, Yunkai Yu, Sunmin Lee, Min-Jung Lee, Keith S. Chan, Rene Costello, Seth M. Steinberg, Bernadette Redd, Hadi Bagheri, Carlos Diaz, Jacqueline Cadena, Olena Sierra Ortiz, Lisa Ley, Lisa Cordes, Biren Saraiya, Sumanta K. Pal, Primo Lara, Rosa Nadal, Amir Mortazavi, Scot A. Niglio, Daniel M. Girardi
Supplementary Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91fac2839c0f806f56fe1cbb014c15e7
https://doi.org/10.1158/1078-0432.22486583.v1
https://doi.org/10.1158/1078-0432.22486583.v1
Autor:
Andrea B. Apolo, Jane B. Trepel, Liang Cao, Donald P. Bottaro, Yang-Min Ning, Howard L. Parnes, Elad Sharon, John J. Wright, Howard Streicher, Antoun Toubaji, Maria Merino, William D. Figg, Vladimir Valera, Heather J. Chalfin, Sandeep Gurram, Yunkai Yu, Sunmin Lee, Min-Jung Lee, Keith S. Chan, Rene Costello, Seth M. Steinberg, Bernadette Redd, Hadi Bagheri, Carlos Diaz, Jacqueline Cadena, Olena Sierra Ortiz, Lisa Ley, Lisa Cordes, Biren Saraiya, Sumanta K. Pal, Primo Lara, Rosa Nadal, Amir Mortazavi, Scot A. Niglio, Daniel M. Girardi
Purpose:This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI).Patients and Methods:A phase I expansion coh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35680e61fde6720351d13f1d7642bf4a
https://doi.org/10.1158/1078-0432.c.6532346
https://doi.org/10.1158/1078-0432.c.6532346
Autor:
Tito Fojo, Susan E. Bates, Doug Price, Phil M. Arlen, Yang-min Ning, William D. Figg, William Dahut, Ravi A. Madan, Jeff Schlom, James L. Gulley, Wilfred D. Stein
Purpose: In solid tumors such as prostate cancer, novel paradigms are needed to assess therapeutic efficacy. We utilized a method estimating tumor growth and regression rate constants from serial PSA measurements, and assessed its potential in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9966401a97dd70f09d20c848637eba3
https://doi.org/10.1158/1078-0432.c.6518242
https://doi.org/10.1158/1078-0432.c.6518242
Autor:
Tito Fojo, Susan E. Bates, Doug Price, Phil M. Arlen, Yang-min Ning, William D. Figg, William Dahut, Ravi A. Madan, Jeff Schlom, James L. Gulley, Wilfred D. Stein
Supplementary Figures S1-S6.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2441cdc1cd163839f8e5c8ace8f0ec3c
https://doi.org/10.1158/1078-0432.22441072.v1
https://doi.org/10.1158/1078-0432.22441072.v1
Autor:
Daniel M. Girardi, Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal, Biren Saraiya, Lisa Cordes, Lisa Ley, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Diaz, Hadi Bagheri, Bernadette Redd, Seth M. Steinberg, Rene Costello, Keith S. Chan, Min-Jung Lee, Sunmin Lee, Yunkai Yu, Sandeep Gurram, Heather J. Chalfin, Vladimir Valera, William D. Figg, Maria Merino, Antoun Toubaji, Howard Streicher, John J. Wright, Elad Sharon, Howard L. Parnes, Yang-Min Ning, Donald P. Bottaro, Liang Cao, Jane B. Trepel, Andrea B. Apolo
Publikováno v:
Clinical Cancer Research. 28:1353-1362
Purpose: This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI). Patients and Methods: A phase I expansion
Autor:
Kassa Ayalew, Yang-Min Ning, Michelle J. Foringer, Susan Leibenhaut, Jenn Sellers, Bei Yu, Phillip D. Kronstein, Agata Higgerson, Camelia Mihaescu, Miguel Rodriguez, LaKisha Williams, Ni A. Khin
Background The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) began collaboration on Good Clinical Practice (GCP) inspections for marketing applications since 2009. The main characteristics of the GCP inspection processes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d6a76c14b31a947cc06ce510955afe
https://doi.org/10.21203/rs.3.rs-1667001/v1
https://doi.org/10.21203/rs.3.rs-1667001/v1
Autor:
Jenn W. Sellers, Camelia M. Mihaescu, Kassa Ayalew, Phillip D. Kronstein, Bei Yu, Yang-Min Ning, Miguel Rodriguez, LaKisha Williams, Ni A. Khin
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:765-766
Autor:
Jenn W. Sellers, Camelia M. Mihaescu, Kassa Ayalew, Phillip D. Kronstein, Bei Yu, Yang-Min Ning, Miguel Rodriguez, LaKisha Williams, Ni A. Khin
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:767-767
Autor:
Yang Min Ning, Yutao Gong, Kirsten B. Goldberg, Ann Marie Trentacosti, Chana Weinstock, Maritsa Serlemitsos-Day, Soma Ghosh, Rosane Charlab, Barbara Fuller, Karen Bijwaard, Mitchell S. Anscher, Shaily Arora, Felicia Diggs, Oluseyi Adeniyi, Ruth Mayrosh, Sarah Zimmerman, Xin Gao, Laleh Amiri-Kordestani, Elaine Chang, Reena Philip, Julia A. Beaver, Pamela Gallagher, Frances Fahnbulleh, Richard Pazdur, Erik Bloomquist, Shenghui Tang, Amna Ibrahim
Publikováno v:
Oncologist
The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castrate-resistant prostate cancer (m